We’ve recently updated our valuation analysis.

Abbisko Cayman Valuation

Is 2256 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2256?

Other financial metrics that can be useful for relative valuation.

2256 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does 2256's PB Ratio compare to its peers?

2256 PB Ratio vs Peers
The above table shows the PB ratio for 2256 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average5.8x
6978 Immunotech Biopharm
3xn/aHK$2.3b
1875 TOT BIOPHARM International
6.4xn/aHK$2.1b
1952 Everest Medicines
0.5x35.2%HK$2.6b
2197 Clover Biopharmaceuticals
13.5xn/aHK$2.7b
2256 Abbisko Cayman
0.8x18.7%HK$2.3b

Price-To-Book vs Peers: 2256 is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (5.8x).


Price to Earnings Ratio vs Industry

How does 2256's PE Ratio compare vs other companies in the HK Biotechs Industry?

Price-To-Book vs Industry: 2256 is good value based on its Price-To-Book Ratio (0.8x) compared to the Hong Kong Biotechs industry average (2.8x)


Price to Book Ratio vs Fair Ratio

What is 2256's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2256 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 2256's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 2256 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2256's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2256's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies